To calculate efficacy and safety of LDV/SOF to HCV genotype 2, Phase 3b randomised non-blinded multiceter trial.

To calculate efficacy and safety of LDV/SOF to HCV genotype 2, Phase 3b randomised non-blinded multiceter trial. - The efficacy and safety of LDV/SOF to HCV genotype 2. (GS-US-337-1903)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022566

Enrollment

Registered

2016-06-01

Start date

2016-06-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HCV genotype 2

Interventions

LDV/SOF treatment for 12 weeks CH or LC SOF/RBV treatment for 12 weeks CH or LC LDV/SOF treatment for 12 weeks CH or LC Not tolerant of RBV

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: CH or LC

Exclusion criteria

Exclusion criteria: HCC

Design outcomes

Primary

Measure	Time frame
SVR with 12 week after treatment	—

Countries

Japan

Contacts

Public ContactMichiharu Komatsu

Shinshu University of Medicine Gastroenterology

komichi@shinshu-u.ac.jp0263-37-2634

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026